Merck in talks to buy cancer biotech Seagen: report
July 07, 2022 at 00:21 AM EDT
Merck & Co is reportedly in talks to acquire biotech company Seagen Inc. in a nearly $40 billon deal that would add to the company's cancer drug portfolio.
Photography by Christophe Tomatis